Key Insight on Three FTSE Stocks: Oxford Biomedica Plc, N Brown Group Plc & Micro Focus International Plc

  • Dec 31, 2019 GMT
  • Team Kalkine
Key Insight on Three FTSE Stocks: Oxford Biomedica Plc, N Brown Group Plc & Micro Focus International Plc

Oxford Biomedica Plc

Oxford Biomedica Plc (LON: OXB) is a cell and gene therapy company. The company has established a vast collection of cell therapy and gene product in the fields of CNS disorders, ophthalmology and oncology. The company has built strong bonding with Bioverativ (part of the Sanofi Group), Novartis, the UK Cystic Fibrosis Gene Therapy Consortium & Imperial Innovations, Boehringer Ingelheim, Santen and Orchard Therapeutics, which provides the company with varied income source and in lieu of access to the knowledgeable property, state-of-the-art manufacture facilities and skills. Additionally, the company has technology rights and licensed products to Boehringer Ingelheim, Sanofi and Axovant.

OXB - News Updates

On 19th December 2019, the Chairman of the Group Dr. Lorenzo Tallarigo purchased 415 ordinary shares of 50 pence each for 643.6 pence per share on the London Stock Exchange. Under the buyback agreement, one-third of Dr Tallarigo’s payments after-tax were used to purchasing ordinary shares in Oxford Biomedica plc every month. Due to this, Dr Tallarigo secures 52,891 ordinary shares which represent 0.07 per cent of the company.

On 19th December 2019, the company announced to expand its supply agreement with Novartis for another five years for the manufacture of Lentiviral Vectors. Under this agreement, the company will gain at least $75 million from Novartis in the next five years.

On 2nd December 2019, the company announced that it issued share capital which consists of 76.8 million ordinary shares of 50 pence each with equal voting rights. However, there are no ordinary shares held in treasury.

OXB – Financial Highlights

On 4th September 2019, the company released its results for the six months ended 30 June 2019.

The company’s revenue decreased by 9 per cent to £32.1 million in H1 FY2019 versus £35.3 million in H1 FY2018. However, commercial development and bioprocessing revenues increased by 23% in H1 FY2019. The operating (loss) / profit was reported at a loss of £6.1 million in H1 FY2019 versus a profit of £9.4 million in H1 FY2018. The company’s (loss) / profit and total comprehensive (expense) / income for the period stood at a loss of £10.2 million in H1 FY2019 versus a profit of £5.2 million in H1 FY2018.

The company’s Basic (loss) / earnings per ordinary share stood at a loss of 14.83 pence in H1 FY2019 as compared to 8.05 pence in H1 FY2018. The company’s diluted earnings per ordinary share decreased to a loss of 14.83 pence in H1 FY2019 as compared to +7.56 pence in H1 FY2018.

OXB – Share Price Performance

On 31st December 2019 as at 09:03 AM GMT, while writing the report OXB share price was trading at GBX 667.92 per share on the London Stock Exchange, which was down by 0.31 per cent or GBX 2.08 per share, as compared to the GBX 670.0 per share, the previous day’s closing price.

The 52-week highest share price was GBX 794.88, which was reported on 29th May 2019, whereas the 52-week lowest share price was GBX 461.50, which was reported on 18th September 2019. The current share price was lower by 15.97 per cent from the 52-week highest price, whereas it was higher by 44.72 per cent from the 52-week lowest price.

The company’s market capitalisation was reported at GBP 514.88 million at the time of writing. The free float of the OXB was reported at 60.10 million and, the share outstanding was reported at 76.85 million.

At the time of writing, the beta of the OXB share was reported at -0.12, which means its volatility is inversely correlated to the benchmark market index’s movement.

N Brown Group Plc

N Brown Group Plc (LON: BWNG) is one of the top 10 UK clothing & footwear digital retailer company. The company is mainly focusing on 20+ and 50+ age of customers group. It offers a wide variety of products, predominantly related to clothing, footwear & homewares and its financial services offering helps consumers in spreading the cost. The company is headquartered in Manchester, where it produces its product. Around, 2,400 people are working for the company in the UK.

BWNG – Financial Highlights

On 10th October 2019, the company announced its half-year results for the twenty-six weeks ended 31st August 2019.

The company’s revenue declined by 5.4% to £432.9 million in H1 FY2020. Also, the product revenue decreased by 9.3%, whereas financial services revenue increased by 2.9% in H1 FY2020.

The company’s gross margin recorded at 53.5% in H1 FY2020, a drop of 70 basis point compared to H1 FY2019.The product gross margin dropped in H1 FY2020 due to the market getting extremely promotional; strategic decisions taken to exit the USA and the impact of store closures in the prior year. Financial services gross margin rose in H1 FY2020 due to the continuous expansion in the quality of the loan book.

The effective tax rate was 20.0 per cent in H1 FY2020 versus 21.7 per cent in H1 FY2019. The overall tax charge was £4.7 million in H1 FY2020 versus £1.1 million credit in H1 FY2019. The company’s Adjusted earnings per share increased to 8.87 pence in H1 FY2020 versus 8.37 pence in H1 FY2019. The statutory earnings per share were 4.95 pence in H1 FY2020 versus a loss of 9.14 pence in H1 FY2019.

BWNG – Share Price Performance

On 31st December 2019 as at 09:19 AM GMT, while writing the report BWNG share price was trading at GBX 160.02 per share on the London Stock Exchange, which was a marginal rise of 0.02 per cent or GBX 0.023 per share, as compared to the GBX 160.0 per share, the previous day’s closing price.

The 52-week highest share price was GBX 163.90, which the company achieved in intraday trade of 31st December 2019, whereas the 52-week lowest share price was GBX 82.95, which was reported on 08th February 2019. The current share price was lower by 2.4 per cent from the 52-week highest price, whereas it was higher by 92.9 per cent from the 52-week lowest price.

The company’s market capitalisation was reported to GBP 456.25 million at the time of writing. The free float was reported at 148.35 million and, the share outstanding was reported at 285.15 million.

At the time of writing, the beta of the BWNG share was reported at 0.94, which means its volatility is low as compared to the benchmark market index’s movement.

Micro Focus International Plc

Micro Focus International Plc (LON: MCRO) is the UK-based global infrastructure software company which helps the clients to run and transform their business. The company’s software delivers the crucial tools which clients need to work, develop, safeguard and analyse their enterprise. The company offers a quick, low-risk route to numerical renovation. The company’s solutions for digital renovation is spread across four key areas: Enterprise DevOps, Hybrid IT Management, Security, Risk & Governance and Predictive Analytics.

MCRO – News & Trading Updates

On 2nd December 2019, the company reported that its share capital comprised of 333.4 million ordinary shares of 10 pence each and an additional 30.2 million ordinary shares were held in Treasury. The voting rights in the company is of 333.4 million shares.

The company announced trading updates on 20th November 2019. The company expects the net debt of $4.3 billion for the period ended 31st October 2019 at a leverage multiple of around 3.2x of adjusted EBITDA after the tax payable in respect of SUSE disposal and share repurchase programme.

MCRO – Share Price Performance

On 31st December 2019 as at 13:00 GMT, while writing the report MCRO share price was trading at GBX 1,068.40 per share on the London Stock Exchange, which was down by 2.59 per cent or GBX 28.40 per share, as compared to the GBX 1,096.80 per share, the previous day’s closing price.

The 52-week highest share price was GBX 2,174.50, which was reported on 04th July 2019, whereas the 52-week lowest share price was GBX 998.0, which was reported on 23rd October 2019. The current share price was lower by 50.87 per cent from the 52-week highest price, whereas it was higher by 7.05 per cent from the 52-week lowest price.

The market capitalisation of the company was GBP 3.65 billion at the time of writing. The free float of the MCRO was reported at 331.56 million and, the share outstanding was reported at 333.38 million.

At the time of writing, the beta of the MCRO share was reported at 1.7, which means its volatility is high as compared to the benchmark market index’s movement.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK